Physico-chemical stability of eribulin mesylate containing concentrate and ready-to-administer solutions

Journal of Oncology Pharmacy Practice

Volumn 20, Issue 3, 2014, Pages 183-189

  Spindeldreier, Kirsten ^a   Thiesen, Judith ^a   Lipp, Hans Peter ^b   Krämer, Irene ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Eribulin mesylate; high performance liquid chromatography; physico chemical stability

Indexed keywords

ERIBULIN; POLYPROPYLENE; SODIUM CHLORIDE; FURAN DERIVATIVE; KETONE; SOLUTION AND SOLUBILITY;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; FREEZING; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STORAGE TEMPERATURE; SYRINGE; TEMPERATURE; ULTRAVIOLET RADIATION; CHEMISTRY; DRUG PACKAGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REPRODUCIBILITY; SOLUTION AND SOLUBILITY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG PACKAGING; DRUG STABILITY; FURANS; KETONES; PHARMACEUTICAL SOLUTIONS; REPRODUCIBILITY OF RESULTS;

EID: 84899812351     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155213492449     Document Type: Article

References (15)

1. Bai RL, Paull KD, Herald CL, et al. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem. 1991 ; 266: 15882-15889
2. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001 ; 61: 1013-1021
3. Zheng W, Seletsky BM, Palme MH, et al. Macrocyclic ketone analogues of halichondrin B. Bioorg Med Chem Lett. 2004 ; 14: 5551-5554
4. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005 ; 4: 1086-1095
5. Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004 ; 64: 5760-5766
6. Towle MJ, Salvato KA, Wels BF, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 ; 71: 496-505
7. Kuznetsov G, TenDyke K and Yu MJ. Anti-proliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. In: AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics, 22-26 October 2007, San Francisco, CA, Abstract.
8. EPAR - European public assessment report, http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/002084/human-med-001427. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 (2011, accessed 9 October 2012).
9. Material Safety Data Sheet, http://www.bdipharma.com/MSDS/Eiasi/ Halaven%2010-09.pdf (2009, accessed 9 October 2012).
10. Direct Healthcare Professional Communication Halaven, http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con146474. pdf (2012, accessed 9 October 2012).
11. SPC - Summary of Product Characteristics, http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/002084/WC500105112.pdf (2011, accessed 9 October 2012).
12. Dubbelman AC, Rosing H, Thijssen B, et al. Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 1149-1155.
13. Desjardins C, Saxton P, Lu SX, et al. A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 ; 875: 373-382
14. Poujol S, Dell'ova M, Bekhtari K, et al. Stability of the ready-to-use solutions of eribulin for intravenous infusion. Ann Pharm Fr. 2012 ; 70: 249-255
15. ICH Q2 (R1) Guideline, http://www.ich.org/fileadmin/Public-Web-Site/ICH- Products/Guidelines/Quality/Q2-R1/Step4/Q2-R1Guideline.pdf (2005, accessed 9 October 2012).